Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.
E ChatziioannouL M Serna HiguitaS KreftL KandolfB DujovicL ReinhardtE TamaraI Marquez-RodasA R F P FortunaA NüblingH NiessnerA ForschnerC GarbeA PopovicB MirjanaF MeierT EigentlerU LeiterL FlatzT SinnbergT AmaralPublished in: ESMO open (2024)
We developed and validated a predictive nomogram for long-term PFS in patients with unresectable stage IV melanoma undergoing first-line anti-PD-1-based immunotherapy.